Daniel J Drucker Selected Research

Daniel J Drucker Research Topics

Disease

60	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2002
38	Obesity 01/2022 - 05/2006
38	Body Weight (Weight, Body) 01/2022 - 03/2003
24	Insulin Resistance 01/2019 - 10/2003
22	Inflammation (Inflammations) 01/2021 - 05/2006
17	Weight Loss (Weight Reduction) 01/2021 - 11/2006
13	Hyperglycemia 11/2018 - 02/2003
10	Hypoglycemia (Reactive Hypoglycemia) 04/2019 - 10/2003
9	Weight Gain 01/2022 - 11/2006
9	Neoplasms (Cancer) 04/2019 - 07/2002
8	Myocardial Infarction 11/2021 - 04/2009
8	Glucose Intolerance 01/2018 - 02/2004
6	Atherosclerosis 11/2021 - 01/2013
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 11/2007
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 07/2009
5	Ischemia 10/2017 - 05/2008
5	Hyperplasia 04/2013 - 04/2010
4	Fibrosis (Cirrhosis) 01/2020 - 01/2013
4	Diabetes Mellitus 08/2017 - 01/2002
3	Nausea 01/2021 - 01/2002
3	Albuminuria 01/2020 - 03/2014
3	Hypertension (High Blood Pressure) 01/2020 - 10/2016
3	Short Bowel Syndrome 04/2019 - 01/2014
3	Pancreatitis 01/2018 - 09/2009
3	medullary Thyroid cancer 01/2018 - 07/2011
3	Infarction (Infarctions) 02/2015 - 04/2009
3	Anorexia 04/2013 - 01/2005
2	Stroke (Strokes) 11/2021 - 01/2018
2	Vomiting 01/2021 - 01/2002
2	Metabolic Diseases (Metabolic Disease) 01/2021 - 01/2017
2	Intestinal Failure 01/2020 - 01/2020
2	Cardiomegaly (Heart Hypertrophy) 01/2020 - 03/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 05/2006
2	Vascular System Injuries 01/2018 - 12/2016
2	Heart Diseases (Heart Disease) 11/2017 - 07/2009
2	Hypertrophy 02/2015 - 01/2013
2	Necrosis 01/2013 - 01/2003
2	Colitis 06/2012 - 02/2002
2	Enteritis 03/2012 - 02/2002
2	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 02/2012 - 12/2004

Drug/Important Bio-Agent (IBA)

62	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2002
61	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 01/2002
32	Glucagon-Like Peptide-1 ReceptorIBA 11/2021 - 09/2005
25	Glucagon (Glukagon)FDA Link 01/2022 - 10/2003
25	IncretinsIBA 01/2019 - 01/2002
18	Insulin (Novolin)FDA Link 01/2022 - 10/2003
15	Liraglutide FDA Link 01/2022 - 11/2006
15	Peptides (Polypeptides)IBA 01/2021 - 01/2002
13	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2018 - 01/2002
12	Hormones (Hormone)IBA 01/2021 - 07/2002
11	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2002
11	Exenatide (Byetta)FDA Link 03/2015 - 01/2003
8	Glucagon Receptors (Glucagon Receptor)IBA 11/2018 - 10/2005
8	Blood Glucose (Blood Sugar)IBA 04/2013 - 01/2002
7	Sitagliptin Phosphate (Januvia)FDA Link 01/2020 - 11/2006
6	semaglutideIBA 01/2022 - 08/2017
6	gastric inhibitory polypeptide receptorIBA 01/2022 - 01/2012
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2008
6	LipidsIBA 01/2020 - 06/2010
6	Glucagon-Like Peptides (Enteroglucagon)IBA 01/2020 - 07/2002
5	LeptinIBA 01/2021 - 01/2008
5	Pharmaceutical PreparationsIBA 01/2021 - 02/2002
5	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 01/2002
5	EnzymesIBA 01/2020 - 05/2007
5	Biological ProductsIBA 10/2019 - 01/2003
5	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 10/2017 - 01/2002
4	Triglycerides (Triacylglycerol)IBA 01/2021 - 04/2008
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2018
4	Messenger RNA (mRNA)IBA 10/2019 - 10/2003
4	Proglucagon (Glucagon Precursors)IBA 04/2019 - 07/2002
4	Streptozocin (Streptozotocin)FDA Link 11/2015 - 11/2008
3	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2020 - 02/2008
3	Therapeutic UsesIBA 10/2019 - 02/2002
3	CytokinesIBA 10/2019 - 01/2003
3	fibroblast growth factor 21IBA 01/2018 - 01/2016
3	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018 - 09/2009
3	Dextran SulfateIBA 06/2012 - 02/2002
3	Glucagon-Like Peptide-2 ReceptorIBA 09/2010 - 10/2005
2	Interleukin-6 (Interleukin 6)IBA 10/2019 - 10/2011
2	teduglutideIBA 04/2019 - 02/2015
2	SugarsIBA 01/2019 - 04/2013
2	Lipoproteins (Lipoprotein)IBA 08/2017 - 09/2009
2	Peptide Hormones (Polypeptide Hormones)IBA 12/2016 - 07/2013
2	CholesterolIBA 10/2016 - 01/2015
2	SodiumIBA 10/2016 - 01/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2016 - 08/2014
2	salicylhydroxamic acid (SHAM)IBA 03/2014 - 02/2003
2	GastrinsIBA 07/2013 - 10/2003
2	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 07/2013 - 01/2002
2	NF-kappa B (NF-kB)IBA 01/2013 - 05/2006
2	ThiazolidinedionesIBA 02/2011 - 01/2006
2	glycogen synthase kinase 3 alphaIBA 10/2008 - 10/2007
2	Glycogen Synthase Kinase 3IBA 10/2008 - 10/2007

Therapy/Procedure

28	Therapeutics 01/2022 - 01/2002
6	Glycemic Control 01/2021 - 06/2010
5	Bariatric Surgery 01/2022 - 07/2013
3	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
3	Injections 01/2021 - 11/2006
2	Ligation 02/2015 - 04/2010
2	Parenteral Nutrition 02/2015 - 01/2014